Navigation Links
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Date:11/18/2008

Randomized study will enroll newly diagnosed, elderly AML patients

PRINCETON, N.J., Nov. 18 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

The first patient was enrolled by Eric Feldman, MD at the Weill Medical College of Cornell University and New York Presbyterian Hospital. Dr. Feldman was an investigator involved in the Phase 1 study with CPX-351 in patients with advanced leukemias. "We are pleased to be involved in this Phase 2 study based on the encouraging results seen in the Phase 1 study," said Dr. Feldman. "It's important to develop new treatment options for patients and CPX-351 incorporates two of the most active agents used in the treatment of AML."

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown in preclinical studies to represent a synergistic ratio for use in combination chemotherapy. CPX-351 represents a new approach to developing drug combinations in which drug ratios are pre-selected based on synergistic anti-tumor activity observed preclinically and where the ratios are maintained in patients through Celator's proprietary CombiPlex(R) technology platform.

The Phase 2 study will be conducted in patients with newly diagnosed AML, greater than or equal to 60 but <76 years of age, who are able to tolerate intensive chemotherapy. This randomized (2:1) study is designed to compare CPX-351 to the conventional method of administering cytarabine and daunorubicin, commonly referred to as "7+3." The reference "7+3" refers to the administration days of the drugs (cytarabine is administered as a 7 day continuous infusion and daunorubicin is administered on days 1, 2 and 3). CPX-351 is administer
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
2. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
3. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
4. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
5. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Raptor Pharmaceuticals Provides Update on Targeting Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015   Physicians Rx ... Bernstein has joined the organization as President and ... recently served as President and Chief Executive Officer for ... Chief Executive Officer of Physicians Rx Pharmacy, be responsible ... "We are extremely pleased to bring Gaston on ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ... "Inhaled Drug Delivery (London, UK - November 19-20, ... Inhaled Drug Delivery meeting will cover industry case studies, ... more. The Co-Chairmen are Dr Steven Nichols , ... Director, Mylan. Companies participating include: ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the addition of ... 16-18, 2015)" conference to their offering. Regulatory requirements for ... Peru , Brazil , ... , Paraguay , Venezuela , ... Chile This seminar can be viewed both as ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... ULURU Inc. (NYSE Amex: ULU ) today ... fourth quarter and year ended 2010 financial results and to provide ... a.m. Eastern Time. To participate in the conference call ... code 23750#) five to ten minutes prior to the initiation of ...
... The Food and Drug Administration (FDA) today approved the use ... of shingles in individuals 50 to 59 years of age. ... of age and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... 200,000 healthy people between the ages of 50 and 59, ...
Cached Medicine Technology:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update 2FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age 2
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 Podcast ... great success in launching their Path11 Podcast with 23 episodes released since April 2015. ... the well known Spiritual Catalyst and Linda Howe, leader in the field of Akashic ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa can ... professionals out there. His perspective on internal medicine keeps patients happy and healthy, something ... is important regardless of the season, but even more so in the fall, when ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... Chris Harrison of Harrison’s Footwear of ... a simple decision, really,” says Chris. “We have a lot of repeat customers, and ... that work best for them—so we’ve given them the convenience of ordering from home.” ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2
... study says , , TUESDAY, Feb. 12 (HealthDay News) -- Americans ... pain, but new research suggests those extra dollars aren,t buying ... the authors of a study in the Feb. 13 issue ... but the lack of results weren,t. , "This calls into ...
... parent of Northwestern Memorial Hospital, appointed,at its January ... Northwestern,Memorial Foundation,s Boards of Directors., Trina D. ... of the Friends of Prentice,board of directors and ... Committee. Gordon is chairman of Boyden World,Corporation,s board ...
... 12 NHS Choices ( http://www.nhs.uk ),the online ... interactive tool aimed,to help people better understand the ... NHS accredited information, the food allergy symptom checker,( ... whether they have either a food allergy or ...
... The recent influenza,outbreaks across the country, resulting in at ... reminder that the influenza virus is a serious disease,and ... influenza hospitalizes more than 20,000 children,younger than 5 years ... and causes,approximately 100 deaths. These statistics are particularly tragic ...
... Feb. 12 A proposed,regulation to improve the ... by fostering the establishment of Patient Safety Organizations,(PSOs) ... Health and Human,Services (HHS)., PSOs are private ... patient safety events reported by health care providers. ...
... jaw adjustment, BLOOMINGTON, Ind., Feb. 12 A ... Medicine is advocating for the medical,community to provide relief ... sometimes deadly sleep apnea by using a common and ... just amazing that a few millimeters of adjustment, bringing ...
Cached Medicine News:Health News: Back Pain Spending Up, Relief Down 2Health News: Back Pain Spending Up, Relief Down 3Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:Childhood Influenza Immunization Coalition Responds to Recent Influenza Outbreaks 2Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 2Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 3Health News:New Patient Safety Proposed Regulation Aims to Improve Health Care Quality and Patient Safety 4Health News:Dental Devices Offer a Simple Solution for Sleep 2Health News:Dental Devices Offer a Simple Solution for Sleep 3
... to do the exams you want: ,Four probe ... the easiest water path probe in the industry, ... exactly what you need to. From full ... chamber, the P60 provides the clarity of images ...
... will find the samaritan AED easy ... medical and rescue professionals) will appreciate ... manual override, and the ECG monitoring ... AED is an exceptionally well-engineered, lightweight ...
... extraordinary combination of features make the ... multi-specialty clinical environment. The versatility and ... hardware allows you to perform a ... high-quality results., ,The ideal choice for ...
Assay for Anti-HTLV-I and Anti-HTLV-II...
Medicine Products: